Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.

abstract：:Age-associated memory impairment (AAMI) is a diagnostic term applied to healthy persons greater than 50 years of age who have experienced a gradual decline in memory that lies within the boundaries of normality. Although the behavioral deficits associated with AAMI are modest in comparison to those associated with dem...

journal_title：Clinical neuropharmacology

authors： Crook TH,Larrabee GJ,Youngjohn JR

更新日期：1990-01-01 00:00:00

abstract：:Prion diseases are invariably fatal. Recently, quinacrine and chlorpromazine have been suggested as immediate candidates for the treatment of Creutzfeldt-Jakob disease and other prion diseases. The objective of this paper was to report on 2 fatal familial insomnia patients whose overall condition worsened despite quin...

journal_title：Clinical neuropharmacology

authors： Benito-León J

更新日期：2004-07-01 00:00:00

abstract：:trans-Dihydrolisuride, a partial dopamine receptor agonist, was tested for its effects on chorea in a double-blind, crossover clinical study in 10 patients with Huntington's disease. In eight patients, a neurophysiological evaluation was also performed. No reduction in choreic movements or improvement in voluntary mov...

journal_title：Clinical neuropharmacology

authors： Stocchi F,Carta A,Berardelli A,Antonini A,Argenta M,Formica A,Agnoli A

更新日期：1989-10-01 00:00:00

abstract：:Midazolam, a potent short-acting benzodiazepine, is a safe and highly effective agent for the control of status epilepticus. Its efficacy in the control of neonatal seizures, however, has not been determined. Six neonates (aged 1-9 days; gestation, 30-41 weeks) developed seizures from a variety of causes. In each case...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Buckley DJ,Gutierrez AR,Gingold M,Bodensteiner JB,Penney S

更新日期：1996-04-01 00:00:00

abstract：:We studied a 67-year-old woman with a sporadic form of hyperekplexia, who experienced 8-10 excessive startle responses to unexpected stimuli per month. Therapy with fluoxetine had a definite beneficial effect. This finding supports the hypothesis that serotonergic mechanisms play a role in this disorder. ...

journal_title：Clinical neuropharmacology

authors： Sechi G,Sotgiu S,Valenti MP,Pitzolu MG,Peterlongo P,Larizza L,Rosati G

更新日期：2000-05-01 00:00:00

abstract：:There is strong evidence to support the hypothesis that the rapid effects of steroids on neurons are membrane-mediated. Rapid steroid effects have been demonstrated in the absence of intracellular receptors, in the presence of RNA or protein synthesis inhibitors, and in response to steroids coupled to large proteins t...

journal_title：Clinical neuropharmacology

authors： Golden GA,Mason PE,Rubin RT,Mason RP

更新日期：1998-05-01 00:00:00

abstract：:The purpose of this study was to evaluate the effect of amantadine sulfate infusion on the N30 component of the median nerve short-latency somatosensory evoked potentials (SSEPs) in patients with Parkinson's disease (PD). Twenty patients with advanced PD and severe motor fluctuations received a 6-day course of amantad...

journal_title：Clinical neuropharmacology

authors： Bostantjopoulou S,Katsarou Z,Georgiadis G,Zafiriou D,Kazis A

更新日期：2002-03-01 00:00:00

abstract：OBJECTIVES:Obsessive-compulsive disorder (OCD) is notably a comorbid disorder in patients with schizophrenia. This study aimed to evaluate clinical features and correlates of early onset patients with schizophrenia with OCD. METHODS:In the present study, we included 10 patients with both schizophrenia and OCD and 19 p...

journal_title：Clinical neuropharmacology

authors： Baytunca B,Kalyoncu T,Ozel I,Erermiş S,Kayahan B,Öngur D

更新日期：2017-11-01 00:00:00

abstract：:Forty patients with different clinical and electrophysiological types of myoclonus were treated with piracetam (18-24 g per day, p.o.) alone, or with other drugs (clonazepam, sodium valproate, and primidone) in different combinations. Piracetam in monotherapy improved the electrophysiological abnormalities in patients...

journal_title：Clinical neuropharmacology

authors： Obeso JA,Artieda J,Quinn N,Rothwell JC,Luquin MR,Vaamonde J,Marsden CD

更新日期：1988-12-01 00:00:00

abstract：:Clozapine often causes low-grade fever and less frequently spiking fever. We describe three cases of spiking fever that occurred in the first 3 weeks of clozapine therapy. A new set of side effects of clozapine is identified, which includes spiking fever, respiratory and gastrointestinal symptoms, and neutrophilia. Po...

journal_title：Clinical neuropharmacology

authors： Trémeau F,Clark SC,Printz D,Kegeles LS,Malaspina D

更新日期：1997-04-01 00:00:00

abstract：OBJECTIVE:Use of antipsychotic agents in the management of various psychopathologies in Child and Adolescent Psychiatric practice is gradually increasing. This study aimed to evaluate the sociodemographic and clinical features of children and adolescents who applied to an outpatient clinic of child and adolescent psych...

journal_title：Clinical neuropharmacology

authors： Yektaş Ç,Tufan AE

更新日期：2018-01-01 00:00:00

abstract：OBJECTIVE:Multiple sclerosis (MS) is a degenerative neurological condition that results in impairments in multiple domains including cognition, fatigue, and mood. Dalfampridine-extended release (D-ER) has been approved to improve walking in persons with MS. It is plausible that D-ER could improve cognition, fatigue, an...

journal_title：Clinical neuropharmacology

authors： Triche EW,Ruiz JA,Olson KM,Lo AC

更新日期：2016-03-01 00:00:00

abstract：:The aim of the present study was to evaluate sexual function and behaviour in male patients who take lithium. Participants included 35 bipolar and schizoaffective men, aged 43.3 +/- 9.6 years, who were in euthymic state and were receiving lithium as the sole medical treatment. Eleven patients (31.4%) reported sexual d...

journal_title：Clinical neuropharmacology

authors： Aizenberg D,Sigler M,Zemishlany Z,Weizman A

更新日期：1996-12-01 00:00:00

abstract：OBJECTIVE:Safety and efficacy of botulinum neurotoxin type A preparation NT 201 (Xeomin, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) were investigated over 52 weeks in a double-blind, randomized trial with 32 male volunteers. METHODS:Electroneurographic assessments with surface electrodes were performed aft...

journal_title：Clinical neuropharmacology

authors： Wohlfarth K,Müller C,Sassin I,Comes G,Grafe S

更新日期：2007-03-01 00:00:00

abstract：BACKGROUND:Topiramate (TPM) is a fructose derivative, which was originally developed as an antiepileptic. In this context, movement disorders (MDs) are possible adverse events secondary to TPM. CASE REPORTS:Two patients (cases 1 and 2) developed myoclonus, and the other 2 had restless leg syndrome (RLS, cases 3 and 4)...

journal_title：Clinical neuropharmacology

authors： Rissardo JP,Caprara ALF

更新日期：2020-07-01 00:00:00

abstract：:A large number of patients with neurosyphilis present dementia with a progressive course and psychiatric symptoms such as depression, mania, and psychosis. Despite prompt and proper antibiotic treatment, the recovery is often incomplete, especially when tissue damage has occurred. We reported a patient with persisted ...

journal_title：Clinical neuropharmacology

authors： Wu YS,Lane HY,Lin CH

更新日期：2015-07-01 00:00:00

abstract：:The standard therapy for myasthenia gravis (MG) includes steroids and immunosuppressants, which have delayed onset of action and significant side effects. Plasmapheresis and intravenous immunoglobulin have been used mostly for the treatment of severe exacerbations. In the present study we examined the use of intraveno...

journal_title：Clinical neuropharmacology

authors： Hilkevich O,Drory VE,Chapman J,Korczyn AD

更新日期：2001-05-01 00:00:00

abstract：:Following oral administration in the fasting healthy subject, the mean maximum concentration of tianeptine is 334 +/- 79 ng/ml. Absorption of tianeptine from the tablet form is rapid and complete. Maximum plasma concentration is obtained by the first hour following administration (0.94 +/- 0.47 h). Absolute bioavailab...

journal_title：Clinical neuropharmacology

authors： Royer RJ,Albin H,Barrucand D,Salvadori-Failler C,Kamoun A

更新日期：1988-01-01 00:00:00

abstract：:Various reactions to benzodiazepine withdrawal have been widely described. Among these, seizures have occasionally occurred on abrupt withdrawal. Our own experience of 48 cases of seizures suspected to have been caused by benzodiazepine withdrawal and reported to the Adverse Drug Reaction (ADR) Monitoring Center (1979...

journal_title：Clinical neuropharmacology

authors： Fialip J,Aumaitre O,Eschalier A,Maradeix B,Dordain G,Lavarenne J

更新日期：1987-12-01 00:00:00

abstract：OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was t...

journal_title：Clinical neuropharmacology

authors： Elble RJ,Lyons KE,Pahwa R

更新日期：2007-11-01 00:00:00

abstract：:Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited. In this study, moclobemide 150 mg twice daily (b.i.d.) was compared to two different three-times-daily (t.i.d.) regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. The study was random...

journal_title：Clinical neuropharmacology

authors： Gagiano CA,Hart GA,Bodemer W,Schall R

更新日期：1994-01-01 00:00:00

abstract：:Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs an...

journal_title：Clinical neuropharmacology

authors： Nolen WA,Hoencamp E,Bouvy PF,Haffmans PM

更新日期：1993-01-01 00:00:00

abstract：:The objective of this study was to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of five fixed doses of ganstigmine (CHF 2819) in patients with probable Alzheimer's disease (AD). This randomized, double-blind, placebo-controlled trial evaluated five dose levels (5, 7...

journal_title：Clinical neuropharmacology

authors： Jhee SS,Fabbri L,Piccinno A,Monici P,Moran S,Zarotsky V,Tan EY,Frackiewicz EJ,Shiovitz T

更新日期：2003-05-01 00:00:00

abstract：:This review examines the features of the 16 randomized controlled trials that have been published on the use of oral tacrine for treating probable Alzheimer's disease and explores the methodologic problems associated with these studies. Patient selection using the standard National Institute of Neurological and Commun...

journal_title：Clinical neuropharmacology

authors： Conway EL

更新日期：1998-01-01 00:00:00

abstract：BACKGROUND:Recent studies indicate that the traditional Japanese herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful for treating behavioral and psychological symptoms in dementia, borderline personality disorder, neuroleptic-induced tardive dyskinesia, and treatment-resistant schizophrenia...

journal_title：Clinical neuropharmacology

authors： Miyaoka T,Furuya M,Kristian L,Wake R,Kawakami K,Nagahama M,Kawano K,Ieda M,Tsuchie K,Horiguchi J

更新日期：2011-01-01 00:00:00

abstract：:Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

journal_title：Clinical neuropharmacology

authors： Giménez-Roldán S,Esteban EM,Mateo D

更新日期：2001-11-01 00:00:00

abstract：:The freely diffusible gaseous compound nitric oxide (NO) has recently been discovered to be an important cellular messenger in many organ systems throughout the body. The importance of NO as an intermediary in cell communication in the brain is highlighted by the fact that the excitatory amino acid glutamate, the most...

journal_title：Clinical neuropharmacology

authors： Karatinos J,Rosse RB,Deutsch SI

更新日期：1995-12-01 00:00:00

abstract：:In a randomized double-blind study, 20 parkinsonian patients (suffering from the disease for 2-18 years), chronically treated with levodopa (500-750 mg/day for 0.5-12 years), received terguride (1 mg b.i.d.) or placebo for 4 weeks. Growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), and insulin-li...

journal_title：Clinical neuropharmacology

authors： Martignoni E,Horowski R,Liuzzi A,Costa A,Dallabonzana D,Cozzi R,Attanasio R,Rainer E,Nappi G

更新日期：1996-02-01 00:00:00

abstract：:The authors compared the two portions of the OFF period in patients with Parkinson disease and response fluctuations: time to ON (the latency from levodopa intake to turning ON) and wearing off (time from termination of the beneficial dose effect until the time when the next dose was taken). Time to ON was more than t...

journal_title：Clinical neuropharmacology

authors： Merims D,Djaldetti R,Melamed E

更新日期：2003-07-01 00:00:00

abstract：:Occipital neuralgia (ON) is described as a shooting, stabbing pain in the posterior part of the scalp that involves the occipital nerve. The epidemiology and pathophysiology are uncertain, but ON is considered distinct from other headache types. At the time of this writing, memantine for the treatment of ON has not be...

journal_title：Clinical neuropharmacology

authors： Hayes WJ,Hoffmann C,Jacobson P,Kotschevar C,Kappes JA,Berendse J

更新日期：2020-11-01 00:00:00